Pharmaceutical

Auris Medical (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “We are making good progress with our AM-125 program for …

Auris Medical (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“We are making good progress with our AM-125 program for the intranasal treatment of vertigo with betahistine,” commented Thomas Meyer, Auris Medical’s founder, Chairman and Chief Executive Officer. “We obtained further animal data confirming the superior bioavailability of intranasal betahistine relative to oral betahistine and look forward to obtaining additional data in humans through our recently initiated second Phase 1 trial. As we prepare to discuss the regulatory pathway for our AM-111 program with health authorities and continue to analyze the outcomes from our Keyzilen® trials, we are reviewing our strategic options focused on enhancing shareholder value.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20748.58+216.40
TSXV724.19+9.53
DOW33212.96+575.77
S&P 5004158.24+100.40
NASD12131.13+390.48
ASX7182.70+76.80

COMMODITIES

Commodities
Gold1853.48+0.45
Silver22.12+0.03
Copper4.32+0.06
Palladium2076.57+13.05
Platinum957.08+2.92
Oil115.07+0.98
Heating Oil3.90+0.05
Natural Gas8.71-0.19

DOWNLOAD FREE REPORTS

×